Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.
Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
CJEM. 2022 Jun;24(4):397-407. doi: 10.1007/s43678-022-00275-3. Epub 2022 Apr 1.
Treatment for coronavirus disease 2019 (COVID-19) evolved between pandemic waves. Our objective was to compare treatments, acute care utilization, and outcomes of COVID-19 patients presenting to emergency departments (ED) across pandemic waves.
This observational study enrolled consecutive eligible COVID-19 patients presenting to 46 EDs participating in the Canadian COVID-19 ED Rapid Response Network (CCEDRRN) between March 1 and December 31, 2020. We collected data by retrospective chart review. Our primary outcome was in-hospital mortality. Secondary outcomes included treatments, hospital and ICU admissions, ED revisits and readmissions. Logistic regression modeling assessed the impact of pandemic wave on outcomes.
We enrolled 9,967 patients in 8 provinces, 3,336 from the first and 6,631 from the second wave. Patients in the second wave were younger, fewer met criteria for severe COVID-19, and more were discharged from the ED. Adjusted for patient characteristics and disease severity, steroid use increased (odds ratio [OR] 7.4; 95% confidence interval [CI] 6.2-8.9), and invasive mechanical ventilation decreased (OR 0.5; 95% CI 0.4-0.7) in the second wave compared to the first. After adjusting for differences in patient characteristics and disease severity, the odds of hospitalization (OR 0.7; 95% CI 0.6-0.8) and critical care admission (OR 0.7; 95% CI 0.6-0.9) decreased, while mortality remained unchanged (OR 0.7; 95% CI 0.5-1.1).
In patients presenting to cute care facilities, we observed rapid uptake of evidence-based therapies and less use of experimental therapies in the second wave. We observed increased rates of ED discharges and lower hospital and critical care resource use over time. Substantial reductions in mechanical ventilation were not associated with increasing mortality. Advances in treatment strategies created health system efficiencies without compromising patient outcomes.
Clinicaltrials.gov, NCT04702945.
针对 2019 年冠状病毒病(COVID-19)的治疗方法在疫情浪潮之间不断演变。我们的目的是比较在疫情浪潮期间,向急诊科(ED)就诊的 COVID-19 患者的治疗方法、急性护理使用情况和结局。
这项观察性研究纳入了 2020 年 3 月 1 日至 12 月 31 日期间参加加拿大 COVID-19 ED 快速反应网络(CCEDRRN)的 46 家 ED 中连续符合条件的 COVID-19 患者。我们通过回顾性病历审查收集数据。主要结局为院内死亡率。次要结局包括治疗方法、住院和 ICU 入院、ED 复诊和再入院。逻辑回归模型评估了疫情浪潮对结局的影响。
我们在 8 个省招募了 9967 名患者,其中 3336 名来自第一波疫情,6631 名来自第二波疫情。第二波疫情患者年龄较小,符合 COVID-19 严重程度标准的患者较少,且更多患者从 ED 出院。与第一波疫情相比,第二波疫情中皮质类固醇的使用增加(优势比[OR]7.4;95%置信区间[CI]6.2-8.9),而有创机械通气减少(OR 0.5;95% CI 0.4-0.7)。在调整患者特征和疾病严重程度差异后,住院(OR 0.7;95% CI 0.6-0.8)和重症监护病房入院(OR 0.7;95% CI 0.6-0.9)的几率降低,而死亡率保持不变(OR 0.7;95% CI 0.5-1.1)。
在向急性护理机构就诊的患者中,我们观察到第二波疫情期间迅速采用了基于证据的治疗方法,而较少使用实验性治疗方法。随着时间的推移,ED 出院率增加,医院和重症监护病房资源使用减少。机械通气的大量减少并未导致死亡率增加。治疗策略的进步在不影响患者结局的情况下提高了卫生系统的效率。
Clinicaltrials.gov,NCT04702945。